Establishment of a SUMO pathway related gene signature for predicting prognosis, chemotherapy response and investigating the role of EGR2 in bladder cancer

Xiao, Han; Huang, Xiaoan; Chen, Heyi; Zheng, Ying; Liu, Weihui; Chen, Jiabi; Wei, Ran; Lin, Ming; Wang, Qingshui; Zhuang, Wei

doi:10.7150/jca.96481



International Journal of Biological Sciences

International Journal of Medical Sciences

Theranostics

Journal of Genomics

Nanotheranostics

Global reach, higher impact

Full Text | PDF

J Cancer 2024; 15(12):3841-3856. doi:10.7150/jca.96481 This issue Cite

Research Paper

Establishment of a SUMO pathway related gene signature for predicting prognosis, chemotherapy response and investigating the role of EGR2 in bladder cancer

Han Xiao^2#, Xiaoan Huang^1#, Heyi Chen^1#, Ying Zheng^3#, Weihui Liu¹, Jiabi Chen¹, Ran Wei^5✉, Ming Lin^1✉, Qingshui Wang^4✉, Wei Zhuang^1✉

1. Department of Urology, The Second Affiliated Hospital of Fujian Medical University, Quanzhou 362000, Fujian, China.
2. Department of Pathology, Fujian Medical University Union Hospital, Fuzhou 350001, Fujian, China.
3. Department of Obstetrics, Fuzhou Second Hospital, Fuzhou 350000, Fujian, China.
4. The Second Affiliated Hospital of Fujian University of Traditional Chinese Medical University Medicine, Fujian-Macao Science and Technology Cooperation Base of Traditional Chinese Medicine-Oriented Chronic Disease Prevention and Treatment, Innovation and Transformation Center, Fujian University of Traditional Chinese Medicine, Fuzhou 350001, Fujian, China.
5. School of Medical and Health Engineering, Changzhou University, Changzhou 213164, Jiangsu, China.
^#: Han Xiao, Xiaoan Huang, Heyi Chen, and Ying Zheng have contributed equally to this work.

Citation:

Xiao H, Huang X, Chen H, Zheng Y, Liu W, Chen J, Wei R, Lin M, Wang Q, Zhuang W. Establishment of a SUMO pathway related gene signature for predicting prognosis, chemotherapy response and investigating the role of EGR2 in bladder cancer. J Cancer 2024; 15(12):3841-3856. doi:10.7150/jca.96481. https://www.jcancer.org/v15p3841.htm

Other styles

Abstract

Background: Bladder cancer is a prevalent malignancy with significant clinical implications. Small Ubiquitin-like Modifier (SUMO) pathway related genes (SPRG) have been implicated in the development and progression of cancer.

Methods: In this study, we conducted a comprehensive analysis of SPRG in bladder cancer. We analyzed gene expression and prognostic value of SPRG and developed a SPRG signature (SPRGS) prognostic model based on four genes (HDAC4, TRIM27, EGR2, and UBE2I) in bladder cancer. Furthermore, we investigated the relationship between SPRGS and genomic alterations, tumor microenvironment, chemotherapy response, and immunotherapy. Additionally, we identified EGR2 as a key SPRG in bladder cancer. The expression of EGR2 in bladder cancer was detected by immunohistochemistry, and the cell function experiment clarified the effect of knocking down EGR2 on the proliferation, invasion, and migration of bladder cancer cells.

Results: Our findings suggest that SPRGS hold promise as prognostic markers and predictive biomarkers for chemotherapy response and immunotherapy efficacy in bladder cancer. The SPRGS prognostic model exhibited high predictive accuracy for bladder cancer patient survival. We also observed correlations between SPRG and genomic alterations, tumor microenvironment, and response to chemotherapy. Immunohistochemical results showed that EGR2 was highly expressed in bladder cancer tissues, and its overexpression was associated with poor prognosis. Knockdown of EGR2 inhibited bladder cancer cell proliferation, invasion, and migration.

Conclusion: This study provides valuable insights into the landscape of SPRGS in bladder cancer and their potential implications for personalized treatment strategies. The identification of EGR2 as a key SPRG and its functional impact on bladder cancer cells further highlights its significance in bladder cancer development and progression. Overall, SPRGS may serve as important prognostic markers and predictive biomarkers for bladder cancer patients, guiding treatment decisions and improving patient outcomes.

Keywords: Bladder cancer, SUMO, EGR2, Chemotherapy response, Prognosis

Citation styles

APA

Xiao, H., Huang, X., Chen, H., Zheng, Y., Liu, W., Chen, J., Wei, R., Lin, M., Wang, Q., Zhuang, W. (2024). Establishment of a SUMO pathway related gene signature for predicting prognosis, chemotherapy response and investigating the role of EGR2 in bladder cancer. Journal of Cancer, 15(12), 3841-3856. https://doi.org/10.7150/jca.96481.

ACS

Xiao, H.; Huang, X.; Chen, H.; Zheng, Y.; Liu, W.; Chen, J.; Wei, R.; Lin, M.; Wang, Q.; Zhuang, W. Establishment of a SUMO pathway related gene signature for predicting prognosis, chemotherapy response and investigating the role of EGR2 in bladder cancer. J. Cancer 2024, 15 (12), 3841-3856. DOI: 10.7150/jca.96481.

NLM

CSE

Xiao H, Huang X, Chen H, Zheng Y, Liu W, Chen J, Wei R, Lin M, Wang Q, Zhuang W. 2024. Establishment of a SUMO pathway related gene signature for predicting prognosis, chemotherapy response and investigating the role of EGR2 in bladder cancer. J Cancer. 15(12):3841-3856.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.